Literature DB >> 32727297

Views on a "Good Death": End-of-Life Preferences and Their Association With Socio-Demographic Characteristics in a Representative Sample of Older Adults in Switzerland.

Carmen Borrat-Besson1, Sarah Vilpert1,2, Gian Domenico Borasio3,4, Jürgen Maurer5.   

Abstract

The current study explores the end-of-life (EOL) preferences of a national representative sample of adults aged 55 and older in Switzerland and shows how these preferences vary by respondents' sociodemographic characteristics and the linguistic region in which they live. Many of the presented EOL attributes are considered as (very) important by a large majority of the older population in Switzerland with significant variations across sociodemographic groups. Specifically, gender is related to psychosocial aspects of EOL, age to the importance attached to avoiding being a burden on the society, and education levels to preferences regarding overtreatment and advance care planning. The results highlight the importance of a personalized, holistic and interdisciplinary approach to EOL and EOL care, since social, psychological, organizational and physical aspects of EOL are rated as (very) important with significant differences in EOL preferences across sociodemographic groups.

Entities:  

Keywords:  attitude; general public; population; survey

Mesh:

Year:  2020        PMID: 32727297     DOI: 10.1177/0030222820945071

Source DB:  PubMed          Journal:  Omega (Westport)        ISSN: 0030-2228


  2 in total

1.  Dimensions of end-of-life preferences in the Swiss general population aged 55.

Authors:  Carmen Borrat-Besson; Sarah Vilpert; Ralf J Jox; Gian Domenico Borasio; Jürgen Maurer
Journal:  Age Ageing       Date:  2022-08-02       Impact factor: 12.782

2.  Life-and-Death Attitude and Its Formation Process and End-of-Life Care Expectations Among the Elderly Under Traditional Chinese Culture: A Qualitative Study.

Authors:  Lei Lei; Quanxi Gan; Chunyan Gu; Jing Tan; Yu Luo
Journal:  J Transcult Nurs       Date:  2021-06-12       Impact factor: 1.959

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.